Show simple item record

dc.contributor.author Ζερβούδης, Στέφανος el
dc.contributor.author Ιατράκης, Γεώργιος Μ. el
dc.contributor.author Πεϊτσίδης, Παναγιώτης el
dc.contributor.author Τσίκουρας, Παναγιώτης el
dc.contributor.author Γαλάζιος, Γεώργιος el
dc.date.accessioned 2015-05-12T16:48:37Z
dc.date.issued 2015-05-12
dc.identifier.uri http://hdl.handle.net/11400/10225
dc.rights Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.source http://www.ncbi.nlm.nih.gov/pubmed/21491823 en
dc.subject Steroid hormones--Therapeutic use
dc.subject Nutrition
dc.subject Psychological support
dc.subject Στεροειδής ορμόνες, Θεραπευτικές ιδιότητες
dc.subject Διατροφή
dc.subject Ψυχολογική υποστήριξη
dc.title Tibolone vaginal versus per os administration in the management of post-menopausal symptoms en
heal.type journalArticle
heal.classification Medicine
heal.classification Gynecology
heal.classification Ιατρική
heal.classification Γυναικολογία
heal.classificationURI http://id.loc.gov/authorities/subjects/sh00006614
heal.classificationURI http://id.loc.gov/authorities/subjects/sh85058092
heal.classificationURI **N/A**-Ιατρική
heal.classificationURI **N/A**-Γυναικολογία
heal.keywordURI http://id.loc.gov/authorities/subjects/sh85128056
heal.keywordURI http://skos.um.es/unescothes/C02780
heal.contributorName Λυμπέρης, Βασίλειος el
heal.contributorName Ναυρόζογλου, Ιορδάνης el
heal.contributorName Ceauşu, I. fr
heal.contributorName Badiu, C. en
heal.dateAvailable 10000-01-01
heal.language en
heal.access forever
heal.recordProvider Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Μαιευτικής el
heal.publicationDate 2009
heal.bibliographicCitation Zervoudis, S., Iatrakis, G., Peitsidis, P., Tsikouras, P., Galazios, G., et al. (2009) Tibolone vaginal versus per os administration in the management of post-menopausal symptoms. In "Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi", 113 (2), p. 471-477. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21491823 [Accessed: 12/05/2015]. en
heal.abstract Tibolone is a selective tissue estrogenic activity regulator effective in the management of climacteric symptoms, without stimulating endometrial and breast tissue proliferation. It is a well-tolerated treatment regimen with minor adverse effects. The purpose of the current trial was to investigate the efficacy of tibolone administration per os versus per vaginal, concerning the treatment of climacteric symptoms. MATERIAL AND METHOD: A total of 64 post-menopausal healthy women aged 44-55 years (mean 52,5) were enrolled in the study. The patients were divided into three groups: Group A with 24 patients receiving per os Tibolone 2.5 mg x 1 daily for 6 months, Group B with 21 patients receiving vaginally Tibolone 2.5 mg x 1 for 6 months and Group C--with 19 patients receiving only hygienodietetics advices and psychological support for 6 months. All subjects underwent a physical examination, including a transvaginal ultrasonography for the measurement of endometrial thickness and a mammography for the assessment of breast density. RESULTS: In Group A and B, climacteric symptoms were similarly reduced with non significant differences between groups: 79% (19 patients) vs 76% (16 patients) reduction for hot flushes and 83% (20 patients) vs 76% (16 patients) for sweating episodes respectively (p > 0.05). Reduction of hot flushes and sweating episodes was observed in only 2 of 19 patients (10.5%) in group C (p < 0.01). Vaginal route had better results on vaginal dryness-dyspareunia in group B (in 14 patients taken tibolone orally-58% vs 16 patients taken tibolone vaginally-76%). No statistically significant difference was found related to urine symptoms between A and B groups. Tibolone by vaginal route did not cause any severe side effects (apart of a slight discharge) and it was equally (or better) tolerated than oral route. No significant alterations in breast density and BIRADS and no increase in endometrial thickness were observed in all study groups. CONCLUSION: Tibolone is effective in relieving climacteric symptoms indifferent from applications-modus: orally or vaginally. However, further and larger studies are required to confirm results. en
heal.publisher US National Library of Medicine en
heal.journalName Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi en
heal.journalType peer-reviewed
heal.fullTextAvailability false


Files in this item

Files Size Format View

There are no files associated with this item.

The following license files are associated with this item:

Show simple item record

Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες Except where otherwise noted, this item's license is described as Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες